1,721,063 research outputs found
Haplo-BMT: which approach?
No full textIn patients with hematologic malignancies, Di Bartolomeo et al report encouraging outcomes after transplantation of granulocyte-colony stimulating factor (G-CSF)– primed unmanipulated bone marrow from human leukocyte antigen (HLA)– haplotype mismatched (haploidentical) related donors, suggesting that this procedure makes haploidentical transplantation available in all transplant centers
Guerra di esperti e scandalo della clorochina. La pandemia e il destino della medicina divisa tra clinica e prove di efficacia
No full text
Killer-cell immunoglobulin-like receptors reactivity and outcome of stem cell transplant.
No full textHaploidentical hematopoietic stem cell transplantation with a megadose T-cell-depleted graft: harnessing natural and adaptive immunity.
No full textFor patients with high-risk acute leukemia who do not have a matched donor or who urgently need a transplant, transplantation from a full human leukocyte antigen (HLA) haplotype mismatched family donor should be considered a viable option. Clinical trials have shown that a strategy for haploidentical transplantation based on the infusion of high numbers of T-cell-depleted hematopoietic progenitor cells and no post-transplant immunosuppression controls bi-directional T-cell alloreactivity, ie, graft rejection and graft-versus-host disease (GvHD) in patients with leukemia. Overall, event-free survival compares favorably with reports of transplants using sources of stem cells other than the matched sibling. This transplant modality has highlighted the crucial role of donor-versus-recipient natural killer cell (NK) alloreactivity in the control of leukemia relapse. Current studies are focusing on rebuilding post-transplant immunity to improve clinical outcomes
Opposing functions of activatory T-cell receptors and inhibitory NK-cell receptors on cytotoxic T lymphocytes.
No full text
- …
